Danaher Gears Up to Post Q1 Earnings: Is a Beat in Store?

  • DHR's first-quarter earnings are likely to have been aided by strength in the Biotechnology segment. However, weakness in the Diagnostics and Life Sciences segments are expected to have hurt.